Zealand Pharma reported updated phase 1b trial data for its dual GLP-1/GLP-2 receptor agonist dapiglutide, with patients on higher dosing regimens experiencing mean body weight reductions of 11.6% over 28 weeks. The trial cohort was predominantly male and did not involve lifestyle modifications, highlighting the drug’s intrinsic potency. Although the mean weight loss narrowly missed a 12% benchmark seen as encouraging by analysts, the results are comparable to leading GLP-1 therapies currently available. Dapiglutide was well tolerated, with no severe adverse events reported, supporting ongoing development for obesity treatment and related metabolic comorbidities.